• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cure Pharmaceutical wins patent approval for fast-dissolving drug delivery platform

November 16, 2021 By Sean Whooley

Cure PharmaceuticalCure Pharmaceutical (OTC:CURR) announced today that it received confirmation of a patent for its Curefilm Blue platform.\

The U.S. Patent Office (USPTO) provided notification to Cure that U.S. Patent No. 11,179,331 (the ’331 patent) is set to issue on November 23, 2021. The ‘331 patent (“Oral Soluble Film Containing Sildenafil Citrate”) covers Curefilm blue.

Oxnard, California-based Cure Pharmaceutical designed Curefilm Blue as an oral soluble film of sildenafil citrate (the active ingredient present in Viagra) for treating erectile dysfunction (ED). The company is seeking approval of the product via the FDA 505(b)(2) regulatory pathway, according to a news release.

Curefilm Blue uses Cure’s patented and proprietary Curefilm fast-dissolving drug delivery platform to deliver the active pharmaceutical ingredient sildenafil citrate, offering a convenient and portable oral film product to replace pills and other delivery methods for a better patient experience.

The company said the ‘331 patent includes a balance of performance characteristics (fast-dissolving and early onset of action) and physical parameters (large mass, small thickness), while Curefilm blue can be administered without water or beverage.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Regulatory/Compliance Tagged With: Cure Pharmaceutical

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS